Aarhus University Seal

A randomized placebo-controlled trial of nicotinamide riboside+pterostilbene supplementation in experimental muscle injury in elderly subjects

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Jonas Brorson Jensen
  • Ole Lindgård Dollerup
  • ,
  • Andreas Buch Møller
  • Tine B Billeskov
  • Emilie Dalbram, Novo Nordisk Foundation Center for Basic Metabolic Research
  • ,
  • Sabina Chubanava, Novo Nordisk Foundation Center for Basic Metabolic Research
  • ,
  • Mads V Damgaard, Novo Nordisk Foundation Center for Basic Metabolic Research
  • ,
  • Ryan W Dellinger, Elysium Health
  • ,
  • Kajetan Trošt, Novo Nordisk Foundation Center for Basic Metabolic Research
  • ,
  • Thomas Moritz, Novo Nordisk Foundation Center for Basic Metabolic Research
  • ,
  • Steffen Ringgaard
  • Niels Møller
  • Jonas T Treebak, Novo Nordisk Foundation Center for Basic Metabolic Research
  • ,
  • Jean Farup
  • Niels Jessen

BACKGROUND: During ageing there is a functional decline in the pool of muscle stem cells (MuSCs) which influences the functional and regenerative capacity of skeletal muscle. Preclinical evidence have suggested that Nicotinamide Riboside (NR) and Pterostilbene (PT) can improve muscle regeneration e.g. by increasing MuSC function. The objective of the present study was to investigate if NRPT-supplementation promotes skeletal muscle regeneration after muscle injury in elderly humans by improved recruitment of MuSCs.

METHODS: 32 elderly men and women (55-80 yr) were randomized to daily supplementation with either NRPT (1000 mg NR + 200 mg PT) or matched placebo. Two weeks after initiation of supplementation, a skeletal muscle injury was induced by electrically-induced eccentric muscle work. Skeletal muscle biopsies were obtained pre, 2h, 2, 8, and 30 days post injury.

RESULTS: A substantial skeletal muscle injury was induced by the protocol and associated with release of myoglobin and creatine kinase, muscle soreness, tissue edema, and a decrease in muscle strength. MuSC content, proliferation and cell size revealed a large demand for recruitment post injury but was not affected by NRPT. Furthermore, histological analyses of muscle fiber area, internal nuclei and embryonic Myosin Heavy Chain showed no effect of NRPT supplementation.

CONCLUSION: Daily supplementation with 1000 mg NR+200 mg PT is safe but does not improve recruitment of the MuSC pool or other measures of muscle recovery in response to injury or subsequent regeneration in elderly subjects.

TRIAL REGISTRATION: NCT03754842.

FUNDING: Novo Nordisk Foundation (Ref. NNF17OC0027242) given to JTT and NJ. JTT, ED, SC, MVD, KT, and TM are supported by the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR). CBMR is an independent Research Center at the University of Copenhagen that is partially funded by an unrestricted donation from the Novo Nordisk Foundation (NNF18CC0034900).

Original languageEnglish
Article numbere158314
JournalJCI Insight
Volume7
Issue19
Pages (from-to)0-14
Number of pages15
ISSN2379-3708
DOIs
Publication statusE-pub ahead of print - 23 Aug 2022

See relations at Aarhus University Citationformats

ID: 279339550